BEAMHealthcare · BiotechnologyThe 15 Wall Street analysts covering Beam Therapeutics, Inc. hold a median 12-month price target of $45 — +90.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 13 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Beam Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (98): Sales and profits are climbing, and climbing faster than before.
Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BEAM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +90.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | Wedbush | Reiterates | Outperform | $65 |
| 25 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $80 |
| 25 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 July 2026 | B of A Securities | Reiterates | Buy | $47 |
| 8 July 2026 | B of A Securities | Reiterates | Buy | — |
| 7 July 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $80 |
| 13 May 2026 | Bernstein | Maintains | Outperform | — |
| 26 Mar 2026 | Citigroup | Maintains | Buy | — |
| 25 Feb 2026 | RBC Capital | Maintains | Sector Perform | — |
| 25 Feb 2026 | Wedbush | Maintains | Outperform | — |
| 20 Feb 2026 | Canaccord Genuity | Initiates | Buy | — |
| 21 Jan 2026 | Bernstein | Maintains | Outperform | — |
| 7 Jan 2026 | UBS | Initiates | Neutral | — |
| 24 Nov 2025 | Evercore ISI Group | Initiates | Outperform | — |
| 10 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Oct 2025 | JP Morgan | Maintains | Overweight | — |
| 15 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Aug 2025 | Barclays | Maintains | Equal-Weight | — |
| 7 May 2025 | Barclays | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BEAM appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Beam Therapeutics, Inc. returned −7.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 10% of US stocks
Cheaper than 39% of US stocks
Cheaper than 79% of US stocks
Higher than 2% of US stocks
Higher than 3% of US stocks
Higher than 1% of US stocks
Higher than 10% of US stocks
Higher than 37% of US stocks
Higher than 21% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Beam Therapeutics, Inc. has a market value of $2.5B and an enterprise value of $1.6B.
Revenue in the twelve months to 30 June 2026: $156.0M. The latest quarter shrank 94.2% year on year.
Net income over the same four quarters: −$85.4M, a −54.7% net margin.
Diluted earnings per share, trailing twelve months: $−0.86.
Free cash flow in the twelve months to 30 June 2026: −$372.8M.
Trailing P/E: −30.2×; forward P/E: −5.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Beam Therapeutics, Inc. employs 540 people — $289K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Beam Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Benzinga reports that 10 stocks met its screener criteria of more than 38% of float sold short, market capitalization above $2 billion, and average daily volume above 1 million shares, based on data as of Oct. 12.
Why it matters — The excerpt describes a broader list of heavily shorted stocks but does not say whether Beam Therapeutics is included.
Beam Therapeutics reported initial Phase 1/2 data for BEAM-301 in GSDIa, describing clinical proof of concept for correction of the R83C mutation and restored endogenous glucose production after a single treatment. The company said key GSDIa endpoints improved with dose and the safety profile was consistent with LNP-based therapies.
Why it matters — The findings provide an early clinical update on BEAM-301’s potential in GSDIa and are relevant to investors tracking the program’s progress.
The article reaffirms Beam Therapeutics as a long-term buy, highlighting its pipeline leadership in AATD gene editing with BEAM-302 and a first-mover advantage, while downgrading Risto-cel's blockbuster potential. It argues that AI-driven competition is unlikely to disrupt Beam in the near term, with AI partnerships potentially serving as a future catalyst.
Why it matters — A Beam watcher would care because the piece focuses on the company's advancing clinical programs and pipeline positioning, framing BEAM-302 and potential AI partnerships as key factors in the company's future trajectory.
Benzinga reported on ten stocks valued above $2 billion each with more than a third of their float sold short, including one company with over 80% of its float shorted. Beam Therapeutics was listed among the stocks featured in this short-interest watch.
Why it matters — A high percentage of float sold short signals significant bearish positioning that a Beam Therapeutics watcher would want to track for market sentiment and potential volatility.
SBS Law has announced that Beam Therapeutics Inc. (BEAM) investors have the opportunity to join a fraud investigation into the company. The firm issued this notice to investors regarding the investigation.
Why it matters — A fraud investigation notice is significant for BEAM watchers because it could signal legal or regulatory scrutiny of the company.
The 15 Wall Street analysts covering Beam Therapeutics, Inc. have a median 12-month price target of $45, with estimates ranging from $26 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Beam Therapeutics, Inc., 13 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Beam Therapeutics, Inc. 46 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Oct 2026, Beam Therapeutics, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +90.3% from the last close, and Ticker Nerd's factor model ranks Beam Therapeutics, Inc. 46 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Beam Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BEAM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $80 over the next 12 months.
Beam Therapeutics, Inc. returned -7.0% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing platform.
The most recent item we track (Benzinga, 13 Oct 2026): "Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse". Benzinga reports that 10 stocks met its screener criteria of more than 38% of float sold short, market capitalization above $2 billion, and average daily volume above 1 million shares, based on data as of Oct. 12.
Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing platform. The company works on therapies designed to make targeted, single-letter changes in DNA without creating double-strand breaks, supporting programs aimed at serious genetic and hematologic diseases. Its current pipeline includes research and clinical candidates across areas such as blood disorders, liver diseases, and other rare conditions. Beam Therapeutics also maintains integrated capabilities in gene editing, delivery, and internal manufacturing to support the development of its therapeutic candidates. Based in Cambridge, Massachusetts, Beam Therapeutics plays a role in the advanced genomics and gene-editing market, where precision medicine approaches are being applied to address diseases with limited treatment options.
CEO Mr. John M. Evans M.B.A. · 540 employees · United States · https://beamtx.com
